Bacterial disease diagnostics imply diagnostic tests of bacterial disease, which facilitate identification of the causal bacterium of an infection and allow for prompt and efficient treatment. Identification of bacteria is important not only for treatment purposes but also for public health surveillance, control of outbreaks, and control of antimicrobial resistance.
Culture tests are some of the most effective and most commonly used means of diagnosing bacterial infection. Clinical specimens (sputum, urine, blood) are incubated in a particular nutrient media in culture tests such that there is an environment for the growth of bacteria.
After incubation, the growth pattern, colony texture, and microscopic features of bacteria are observed. Although slow (usually 24–72 hours), culture tests are very sensitive and permit follow-up antimicrobial susceptibility testing for directing targeted therapy.
Microscopy is used to view stained or unstained specimens in the microscope to see the bacterial cells. The methods like Gram stain give crucial information regarding the bacterial cell wall (Gram-positive or Gram-negative), shortening the list of the suspected pathogens when in a hurry. Microscopy may be supported by culture or other diagnostic methods to give rapid preliminary information, particularly in low-resource environments or in emergency situations.
Biochemical analysis is used to determine the enzymatic and metabolic characteristics of bacteria, for speciation. Biochemical analysis exposes bacterial responses to substrata like sugars, amino acids, or enzymes (e.g., catalase, oxidase, urease). API strips and computer-assisted systems like VITEK are instances of biochemical identification systems. Such analysis is often conducted after preliminary culture and results in quicker identification than traditional culture alone.
Molecular diagnosis like PCR (polymerase chain reaction) can identify bacterial RNA or DNA from a clinical specimen directly. Molecular diagnostics are also sensitive and specific tests that detect even small levels of bacteria without culture. Molecular diagnosis is particularly helpful in identifying slow growers and difficult-to-grow organisms like Mycobacterium tuberculosis, and with them it is possible to identify resistance genes quickly, hence they are quite helpful for management of drug-resistant infections.
Serological tests perform the functionality of detecting antigens or antibodies in the patient’s blood, which denote past or current infection due to bacteria. These tests help when bacteria can’t be detected in the first go. Helicobacter pylori or Brucella are examples of such infections and Elisa and agglutination tests are examples of such tests. Serological testing is useful in epidemiological surveys and diagnosis of systemic infections as well.
Innovations pertaining to diagnostic technology are facilitating point-of-care testing of the bacterial disease, which is faster, portable, and more accessible. Technologies such as loop-mediated isothermal amplification (LAMP), real-time PCR, and microfluidic-based assays are reported to provide results with immediate effect.
The prevalence of infectious diseases, particularly bacterial diseases, is steadily on the rise globally due to population growth, urbanization, and changed lifestyles. Tuberculosis, pneumonia, cholera, and urinary tract infections (UTIs) are among the most prevalent bacterial diseases that are also causing a considerable amount of morbidity and mortality globally.
With infection rates increasing, never has there been such a demand for quality and timely diagnosis that would recognize the particular causative bacterial pathogens involved. All this growing pathology is fueling high demand for next-generation diagnostic technologies to better detect and treat bacterial infection and propel the industry forward.
The increase in the number of epidemics and outbreaks of bacterial diseases speeds up the need for diagnostic tests for bacterial diseases even further. Outbreaks of certain diseases like multidrug-resistant tuberculosis (MDR-TB), drug-resistant E. coli, and the other types of bacterial pneumonia are on the increase.
Enabling quick detection and identification of the etiologic bacterial strains in these epidemics are essential to control as well as cure them. Reagents used in diagnosis with the ability to screen pathogenic bacteria and resistance types easily are critical in the regulation of such epidemic outbreaks and therefore increasingly sophisticated bacterial disease diagnosis is on the rise.
Enhanced hospital-acquired infections (HAIs), caused in most instances by antibiotic-resistant microbes, is another major driver for bacterial disease diagnosis. Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and Clostridium difficile are a few of the examples of these types of infections that have posed a leading healthcare problem in systems globally.
Technological innovation has greatly facilitated the development of point-of-care (POC) diagnostic devices yielding results quickly at the bedside or remotely from the patient. Such devices such as lateral flow assays and portable PCR allow the healthcare professionals to directly diagnose bacterial infections in real-time without waiting for laboratory results.
The capacity to instantly diagnose pathogens and treat them immediately on the field has been a game changer for bacterial disease management, especially in emergency and limited-resource use.
Molecular testing such as PCR and NGS has revolutionized the diagnosis of bacterial infection to support detection of bacterial pathogens with high sensitivity and specificity. The methods have direct detection of bacterial RNA or DNA from patients' samples without passing through culture.
Molecular tests can quickly diagnose a high proportion of non-cultivatable or slowly growing pathogens, including Mycobacterium tuberculosis or Chlamydia trachomatis. As molecular diagnostics become cheaper, simpler, and more convenient to apply, they create growing demand, both - in the clinic and for field use.
Seamless and expandable efficiency in bacterial disease screening has been notably enhanced with automatic diagnosis. Computerized systems of bacterial detection for biochemical as well as culture-dependent tests allow the high-throughput testing with negligible or no involvement of humans.
Computerized systems can quickly screen and process extremely large numbers of samples, and hospitals can carry out more volume of diagnostic testing without compromising on quality. The development of automated systems and robotically built machinery for bacterial diagnosis increases productivity, minimizes the cost of labor, and provides consistent and correct results, to which they are highly desirable for large-scale diagnostic environments such as clinics, hospital labs, and diagnostic centers.
In terms of region, the global bacterial disease diagnostics industry is classified into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America has the largest market share in the bacterial disease diagnostic market owing to several factors, such as a strong healthcare infrastructure, high healthcare expenditure, and a stringent regulatory environment. The region has advanced hospitals, diagnostic labs, and research network that are at the forefront of adopting new diagnostic technologies.
The United States alone has a dominant presence of the world's most prominent diagnostic companies, which further aid in the commercialization and introduction of novel solutions for diagnosing bacterial diseases.
Current market trends in bacterial disease diagnostics are towards increasing diagnostic speed, accuracy, and accessibility. Molecular diagnostic advancements including CRISPR-based and next-generation sequencing (NGS) technologies allow for quick and accurate detection of bacterial pathogens, including antibiotic-resistant pathogens.
Key players operating in the global bacterial disease diagnostics market include:
NA
NA
NA
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Bacterial Disease Diagnostics Market
